Kornimate/medical-research-clean huggingface dataset:
evaluation of efficacy of microneedling and topical methotrexate versus microneedling and topical 5-flourouracil in treatment of vitillgo patients

Conditions: Vitiligo

Summary: vitiligo is a depigmenting skin disorder, characterized by the selective loss of melanocytes, which in turn leads to loss of pigment in the affected areas of the skin it considerd as autoimmune disease, associated with genetic and environmental factors together with metabolic, oxidative stress and cell detachment abnormalities the disease affects both genders equally, it can appear at any age, and the average age of onset is somewhat variable in different geographic . with an estimated prevalence of 0.5-2% of the population in both adults and children worldwide 5-flourouracil is an antimetabolite analogue of the naturally occurring pyrimidine uracil which is metabolised via the same metabolic pathways as uracil due to its antimitotic activity, topical 5-flourouracil is a useful therapy for the treatment of many dermatological disorders characterized by a high mitotic rate clinically, localized hyperpigmentations have been reported during systemic treatment of various cancers by 5-flourouracil. usually, these hyperpigmented lesions are located on the normally pigmented extremities (hands and feet) and tongue. methotrexate as an antimetabolite and antifolate drug is a time-tested effective treatment extensively used in various autoimmune disorders in low to moderate doses with good efficacy, safety, and tolerability on a long-term basis . methotrexate treatment resulted in the decrease of the number of tnf-α-producing t cells, whereas the number of t cells producing il-10 after polyclonal activation increased, in another study .


Eligibility criteria:
inclusion criteria: * • age :main 18 and above years old. * stable vitiligo (each patient has 3separated patches of depigmentation at least). exclusion criteria:• history of keloid formation. * patients with systemic diseases (diabetes, bleeding disorders) * patients who are receiving chemotherapy or radiotherapy
assessment of the wound healing efficacy and tolerance of a medical device on wounds in healthy subjects.

Conditions: Healthy

Summary: the tested medical device is indicated for the treatment of wounds and small skin injuries. the intention of this study is to evaluate the tolerance and efficacy of the test product by measuring the recovery of the skin barrier after wound produced by suction blister. but also, by validating the accompanying physiological effect of the study product during this recovery.


Eligibility criteria:
inclusion criteria: * subject with a phototype i, ii or iii according to the fitzpatrick scale * subject aged between 18 and 45 years included at selection visit * subject with absence of infectious diseases (hiv and hepatitis), confirmed by negative blood test results exclusion criteria: * history of keloids and hypertrophic scars * subject with removal of axillary lymph nodes * pathology, active skin disease or dermatological condition in progress (psoriasis and/or lichen ruber and/or eczema ...) or presence of dermatological lesions on the inner side of the forearm (solar erythema or dermatosis ...) that may affect the performance of the research or judged incompatible with the realization of the study * subject with severe illness (severe infectious disease (e.g. severe flu)), chronic disease or acute evolutionary pathology likely to influence the study results or considered by the investigator hazardous for the subject or incompatible with the study * knowledge of acquired immunodeficiency syndrome or infectious (acute) hepatitis * subject presenting a healing pathology or a pathology with consequences on the healing like the diabetes mellitus (type i and type ii) * subject with congenital methemoglobinemia or porphyria

Keywords: heaklthy adult subject wound
lidocaine patch for postoperative analgesia after laparoscopic cholecystectomy

Conditions: Postoperative, Pain

Summary: the investigators hypothesized that application of a 5% lidocaine patch would be associated with reduced pain scores after operation compared with placebo patch in patients undergoing laparoscopic cholecystectomy.

* the 5% lidocaine patch have been approved for the treatment of postherpetic neuralgia. * the investigators hypothesized that application of a 5% lidocaine patch would be associated with reduced pain scores, pain controlled drug(opioids, nsaid) in post operative period.

Eligibility criteria:
inclusion criteria: * patients of asa ⅰ-ⅱ * aged 18\~65 * scheduled to undergo elective laparoscopic cholecystectomy under general anesthesia. exclusion criteria: * patients with chronic pain * patients with taking regular analgesics * patients with allergy to ketorolac or lidocaine

Keywords: lidocaine patch laparoscopic cholecystectomy
evaluation of a new radiotracer (68ga-nota-ae105) for diagnosing aggressive cancer with positron emission tomography

Conditions: Breast Cancer; Prostate Cancer; Urinary Bladder Cancer

Summary: the primary objective of the study is to test a new radiotracer called 68ga-nota-ae105 for pet imaging of upar (urokinase plasminogen activator receptor). the tracer has the potential of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and less aggressive tumors. this is a first in human study to test the radiotracer in cancer patients. the biodistribution and tumor uptake will be evaluated by repeated pet imaging (10 minutes, 1 hour and 2 hours post injection).

the primary objective of the study is to test a new radiotracer called 68ga-nota-ae105 for pet imaging of upar (urokinase plasminogen activator receptor). the tracer has the potential of identifying the invasive cancer phenotype, thereby distinguishing between aggressive and less aggressive tumors. this is a first in human study to test the radiotracer in cancer patients. the biodistribution and tumor uptake will be evaluated by repeated pet scans (10 minutes, 1 and 2 hours post injection). the primary end points are safety, biodistribution and dosimetry of 68ga-nota-ae105. in addition, the quantitative uptake of 68ga-nota-ae105 will be compared to the expression of upar measured directly in tumor tissue obtained by surgery or biopsies. the project will be monitored and evaluated in accordance with the principles of good clinical practice (gcp).

Eligibility criteria:
inclusion criteria: 1. diagnosed with cancer of prostate, breast or urinary bladder 2. capable of understanding and giving full informed consent exclusion criteria: 1. pregnancy 2. lactation 3. contraindication for the use of intravenous ct contrast-agencies 4. claustrophobia
the reproducibility of microvascular flow imaging in fibroids and its correlation with 2d and 3d power doppler outcomes

Conditions: Fibroid Uterus

Summary: the investigators hypothesized that macrovascular flow imaging could contribute to 2d power doppler and 3d power doppler in depicting fibroid vascularity. however, data concerning the feasibility and reproducibility of macrovascular flow imaging is lacking. therefore the purpose of our study was to determine 1) the reproducibility of macrovascular flow imaging, 2) its correlation with 2d and 3d power doppler, and 3) penetration depth, in order to investigate the added value for daily clinical practice.


Eligibility criteria:
inclusion criteria: * one or more uterine fibroids * diameter between 1,5 and 12 cm * fibroid easily recognizable on ultrasound exclusion criteria: * younger than 18 years * pregnancy * uterine or cervical malignancy * adenomyosis.

Keywords: fibroid microvascular flow power doppler
assessment of siemens' gobrain and dotbrain software

Conditions: Headache

Summary: our main approach in this research is to collect mr data using both a "routine" and "fast" brain protocol on the 3 tesla siemens skyra scanner using a 20-channel head/neck coil to determine if the "fast" protocol can collect data in less time without compromising patient care.


Eligibility criteria:
inclusion criteria: * patients referred for mri with history of headaches exclusion criteria: * patient does not meet mri safety criteria * patient has known brain pathology
comparison of long vs. short acting anesthesia for improving pain management after breast biopsy

Conditions: Pain Management After Breast Biopsy

Summary: this study will evaluate the potential role of a long acting anesthetic (ropivacaine) in providing an extended period of pain relief for patients undergoing ultrasound guided core biopsy of the breast.

the purpose of this study is to evaluate the potential role of a long acting anesthetic (ropivacaine) in providing an extended period of pain relief for patients undergoing ultrasound guided core biopsy of the breast. one group of patients will receive lidocaine alone for local anesthesia. a second group of patients will similarly receive lidocaine prior to tissue sampling, followed by infiltration of the biopsy area with ropivacaine. our hypothesis is that patients who receive a long acting anesthetic (ropivacaine) along with the popular short acting anesthetic (lidocaine), will be pain free after the breast biopsy procedure for a longer period of time than the patients who only receive lidocaine (the short acting anesthetic). this will lessen the emotional and physical trauma associated with the procedure and give patients a better experience thereby improving patient care.

Eligibility criteria:
inclusion criteria: * patients with breast lesions recommended for biopsy by physician exclusion criteria: * patients with breast lesions not recommended for biopsy * patients with allergic reactions to lidocaine, ropivacaine, or related anesthetics

Keywords: breast biopsy ultrasound lidocaine ropivacaine breast lesion
shoulder muscle imbalance as a risk for shoulder injury in elite adolescent badminton players

Conditions: Sport Injury; Shoulder Injuries

Summary: background: to assess the impact of pre-season clinical measures and rotator muscles strength on the risk of significant shoulder injury (ssi) in elite adolescent badminton players design: prospective cohort study participants: nine elite adolescents badminton players were included and followed from september 2018 to may 2019. independent variables: a pre-season visit consisted in clinical and isokinetic shoulder strength testing. isokinetic internal and external rotator shoulder muscles strength was tested at 60, 120 and 240°/s. conventional and functional (eccentric-to-concentric) ratios (fr) were calculated. ssi collection was performed by an experienced sport physician.


Eligibility criteria:
inclusion criteria: * all the elite adolescent badminton players from a high-level club. exclusion criteria: * players who had ssi in the 3 months prior to the isokinetic test or had shoulder surgery
lansoprazole tablets special drug use surveillance gastroesophageal reflux disease with dyspepsia symptoms

Conditions: Gastroesophageal Reflux Disease With Dyspepsia Symptoms

Summary: to evaluate the efficacy of 4-week lansoprazole (takepron) therapy for subjective symptomatic improvement in gastroesophageal reflux disease patients with dyspepsia symptoms

this is a special drug use surveillance of lansoprazole (takepron) with a 4-week observational period, designed to evaluate the efficacy in gastroesophageal reflux disease patients with dyspepsia symptoms (planned sample size, 15000). the dosage regimen is as follows: * for reflux esophagitis, the usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks. for maintenance treatment of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. if insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily. * for non-erosive gastroesophageal reflux disease, the usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks.

Eligibility criteria:
inclusion criteria: 1. patients with heartburn or acid regurgitation at the start of takepron administration\* , or patients without heartburn and acid regurgitation, but with endoscopic findings classified as los angeles grade a-d at the start of takepron therapy. 2. patients with symptoms of dyspepsia (i.e., postprandial fullness, early satiation, epigastric pain, epigastric burning, upper abdominal bloating, nausea/vomiting, or belching) at the start of takepron administration\* \*these patients must have answered "never, " "sometimes/mild," "often/moderate," or "frequent/severe" on a 4-point scale questionnaire about subjective symptoms. exclusion criteria: 1. patients who have taken any proton pump inhibitors (including takepron) within 4 weeks before the start of takepron administration 2. patients taking antidepressants
development, reliability and validity of the telerehabilitation usability questionnaire- truq

Conditions: Neurological Disease

Summary: neurological diseases are central nervous system diseases that cause an increase in the level of disability and limitations in daily life. multiple sclerosis (ms), stroke, and parkinson's disease (pd) are among the most common apparent neurological diseases, and epidemiological studies show that their prevalence has increased over time worldwide. although ms, stroke, and pd have different causes and neurological aspects, they generally cause motor, sensory, and/or cognitive impairments, leading to restriction of the individual's activities and participation. today, physiotherapy and rehabilitation approaches together with optimal medical and surgical treatment are the cornerstones of treatment for these diseases. recently, it has been stated that various telerehabilitation interventions in the field of physiotherapy and rehabilitation may be an additional option to the rehabilitation approaches applied in the clinic. on the other hand, it is important to evaluate the level of usability in expanding the usability of telerehabilitation services and determining the best telerehabilitation service. for this reason, there is a need for questionnaires investigating the satisfaction level of physiotherapy and rehabilitation applied through telerehabilitation.

questionnaire items will be created in two stages. first, 5 experts will independently review the literature on "telerehabilitation" and "usability". in addition, these experts will be asked to create a pool of questions based on their experiences in telerehabilitation and by taking the opinions of patients receiving telerehabilitation about usability. then, 5 experts will come together and obtain a single question pool containing the questions they deem important in their question pool. the second step will involve scaling the elements. in this study, scale items will be scored on a five-point likert scale, ranging from 1, strongly disagree to 5, strongly agree. then, it will be applied to a pilot group of 10 people and it will be evaluated whether the items prepared by the experts are understood by the patients. in line with the expert opinion and the result of the pilot study, the final version of the scale will be decided and applied to ms, pd, and stroke patients who make up the study group. finally, the validity and reliability of the questionnaire will be calculated.

Eligibility criteria:
inclusion criteria: * voluntarily participate in research to accept * mini-mental test score more than or equal 24 * previously receiving physical therapy through telerehabilitation exclusion criteria: * any visual, hearing, and perception problems that may affect the answering the questionnaire items

Keywords: multiple sclerosis parkinson disease stroke usability telerehabilitation
anesthetic efficacy of 1.8 ml versus 3.6 ml of 4% articaine buccal infiltration

Conditions: Symptomatic Irreversible Pulpitis

Summary: the aim of the study is to compare the anesthetic efficacy and need for supplemental anesthesia of 1.8 ml compared to 3.6 ml of 4% articaine buccal infiltration in mandibular molars with symptomatic irreversible pulpitis.

patients with moderate-to-severe pain due to symptomatic irreversible pulpitis will be included. patients will be randomly assigned into two groups to receive either 1.8 ml 4% articaine buccal infiltration or 3.6. ml 4% articaine buccal infiltration before single visit root canal treatments. intraoperative pain will be assessed using an 11-point numerical rating scale (nrs) so that anesthetic success will be defined as no to mild intraoperative pain. the need for supplemental anesthesia will also be recorded.

Eligibility criteria:
inclusion criteria: 1. healthy patients who are categorized as i or ii according to the american society of anesthesiologists (asa class i or ii). 2. no sex predilection 3. patients with symptomatic irreversible pulpitis 4. patient with the ability to understand and use pain scales. 5. patients who accept to enroll in the study. exclusion criteria: 1. patients' allergies to any of the drugs or materials used in the study. 2. pregnant and lactating females. 3. patients taking analgesics in the last 6-8 hours. 4. patients having more than one symptomatic tooth in the same quadrant
d-dimer-based indication for transesophageal echocardiography to exclude left atrial thrombus before cardioversion of non-anticoagulated atrial fibrillation: a multicenter belgian study

Conditions: Atrial Fibrillation

Summary: this trial aims at evaluating the number of thromboembolic events post cardioversion in patients receiving a direct current cardioversion with either prior transesophageal echocardiography or d-dimer (dd) analysis. patients in need of a direct current cardioversion (dccv), meeting the criteria for dccv with prior transesophageal echocardiography (tee), will be asked to participate in the carddi-bel study. patients will be randomized on a 1:1 ratio to the tee-group or dd-group. patients in the tee-group will receive tee prior to cardioversion to exclude left atrial thrombus according to current guidelines \[1\]. in patients randomized to the dd-group, d-dimer will be analyzed (cut-off defined by ddage). if the ddage \> 10x patient's age, the analysis is suggestive for the presence of left atrial thrombus and the cardioversion will be performed with prior tee. in case of negative ddage, no tee will be used in the dd-group.


Eligibility criteria:
inclusion criteria: * patients older than 18 years * patients with non-valvular atrial fibrillation scheduled for direct current cardioversion with prior tee according to current guidelines * patients willing to sign informed consent exclusion criteria: * cardiac surgery within the previous 90 days. * coronary percutaneous transluminal coronary angioplasty/stenting within the previous 90 days or myocardial infarction within the previous 60 days. * significant congenital anomaly or other medical problem that in the opinion of the investigator would preclude enrollment * history of blood clotting disease or bleeding abnormalities. * patients with valve implants * women who are pregnant * aortic aneurysm or dissection * documented history of deep vein thrombosis within the last 6 months * documented history of pulmonary embolism within the last 6 months * unwilling or unable to provide informed consent. * recent transient ischemic attack or stroke (90 days) * instable angina
oral azacitidine maintenance post-cpx 351

Conditions: Acute Myeloid Leukemia

Summary: approximately 10% of patient develop aml after chemotherapy or radiation for unrelated disease (t-aml) and 20% have aml with an antecedent hematologic disorder (aml-mrc). cpx-351 (vyxeos), a liposomal formulation of a fixed molar ratio (1:5) daunorubicin and cytarabine, has been approved for treatment of adults with newly diagnosed t-aml or aml-mrc. cpx-351 significantly improved median overall survival. although induction chemotherapy results in remission in many older patients with aml, relapse is common and overall survival is poor. for patients not eligible for hsct, maintenance therapies are needed to reduce the risk of relapse and prolong overall survival without causing undue adverse effects or compromising health-related quality of life. oral azacitidine (onureg) has been approved by fda on september, 2020, to treat adult patients with aml who achieved cr or cri following intensive induction chemotherapy with or without consolidation and who are not able to complete intensive curative therapy (not candidate to hsct). the use of oral azacitidine maintenance is an integral part of clinical practice for aml patients who have achieved a first complete remission (cr) or complete remission with incomplete blood count recovery (cri) after intensive ""3+7"" induction chemotherapy and who are unable to complete intensive curative therapy. but there are few data on its efficacy as a post-cpx-351 maintenance agent in patients with newly diagnosed t-aml or aml-mrc or de novo aml.the aim of this study is to show the improvement of overall survival with use of oral azacitidine as maintenance for patients with de novo aml including t-aml or aml-mrc who achieved complete remission or complete remission with incomplete blood count recovery after cpx-351. long-term product safety is also being studied


Eligibility criteria:
inclusion criteria: * male or female subjects \> 64 years of age at the time of c1j1 cpx-351 * de novo aml including t-aml or aml-mrc according to who 2016 * should have undergone induction therapy with cpx-351 with or without cpx-351 consolidation * patients in first line of treatment * should have achieved first cr/cri/crh status according to iwg criteria * ecog performance status of 0,1,2,3 exclusion criteria: * prior bone marrow or stem cell transplantation * patients having achieved cr/cri following an added therapy * patients alive at the start of the study who did not receive study information or who objected to the collection of data

Keywords: onureg aml de novo
curative chemoradiation of low rectal cancer

Conditions: Rectal Cancer

Summary: the aim of the present study is to investigate whether curative chemoradiation of low rectal cancer is feasible, safe and effective in a multicenter study with results comparable to those of single center studies. results from previous studies indicate that a considerable fraction of patients with low rectal cancer can be cured by a combination of radiation and chemotherapy alone and thus be spared from operation.


Eligibility criteria:
inclusion criteria: * histopathologically verified adenocarcinoma of the rectum * planned abdominoperineal resection (apr) or ultralow resection * primary, resectable t1-t3, n0 tumor. n1 nodal disease is acceptable, if the positive lymph nodes are localized to the mesorectum at the level of the tumor. * distance from anal verge to lower edge of tumor ≤ 6 cm measured by rigid rectoscope * performance status 0-2 * patient acceptance to collection of biopsies and blood samples for translational research * age ≥ 18 years * normal function of bone marrow as evaluated by * neutrophils ≥ 1.5 x 10\^9/l * thrombocytes ≥ 100 * normal function of liver * alanine aminotransferase (alat) \< 2.5 x upper limit of normal * bilirubin \< 2.5 x upper limit of normal * kidney function - serum creatinine \ 30 ml/min * fertile women must present a negative pregnancy test and use secure contraceptives during and 3 months after treatment. * written and orally informed consent exclusion criteria: * previous surgical treatment of the present cancer, including transanal excision of tumor. * other malignant disease within the past five years except basocellular skin cancer and carcinoma in situ cervicis uteri * distant metastases verified by imaging or biopsy * previous radiation treatment of the pelvis * pregnant or breastfeeding women